Safety evidence in the use of Ivermectin in pregnants: A purpose of the use of Ivermectin in COVID-19

• Autor: Flores-Cortez, Daisy
• Formato: artículo
• Fecha de Publicación: 2020
• Institución: Sociedad Materno Fetal
• Repositorio: Revista Internacional de Salud Materno Fetal
• Lenguaje: español
• OAI Identifier: oai:ojs2.ojs.revistamaternofetal.com:article/182
• Enlace del recurso: http://ojs.revistamaternofetal.com/index.php/RISMF/article/view/182
• Nivel de acceso: acceso abierto
• Materia: COVID-19; Ivermectina; Embarazo

Ivermectin, a macrocyclic derivative drug made up of an 80:20 mixture of avermectin B1a and B1b, has been used for over 30 years to treat various parasitic diseases in mammals, it was approved by the Food and Drug Administration (FDA) for treatment onchocerciasis and strongyloidiasis, and in other countries its use in scabies and pediculosis was included; however, its spectrum of action includes multiple endo and ectoparasites; as well as its proven effectiveness for the prevention and control of malaria. In a recent in vitro study in Vero / hSLAM cells infected with the SARS-CoV-2 virus (COVID-19) exposed to 5 µM Ivermectin; after 48 hours, it obtained a reduction of the viral RNA in 5000 times compared to the control group. Since then, more than 30 clinical trials will be in the recruitment phase to evaluate the efficacy of Ivermectin in the treatment or prophylaxis of SARS-CoV-2; so it is estimated that in the coming months there will be published results in this regard.